If you think Bayer’s recent $180 million sale of a drug manufacturing facility in Germany means the company is scaling back on production in its home country, think again.
Bayer plans to invest 1.4 billion euros ($1.55 billion) in its pharmaceuticals production sites in Bergkamen, Berlin, Leverkusen, Weimar and Wuppertal in the coming years, the German native said Thursday.
The money will be directed toward adding innovative technologies, new production facilities and digitization.
